Factor II (Prothrombin) Mutation
Factor II (prothrombin) is a common hereditary mutation that is associated with increased prothrombin and thrombin levels, which increase an individual’s risk for venous thromboembolic diseases at an early age. Common diseases associated with the prothrombin mutation include blood clots, deep vein thrombosis (DVT), and pulmonary embolisms (PE). It is the second most common (after Factor V Leiden) genetic cause of venous thrombosis and is found in 18% of patients that have a family history of venous thrombosis. Within the general population, 1 - 2% of the US population, 3.0% of southern European populations, and 1.7% of northern Europeans have the mutation.
The Factor II mutation is due to a single base-pair change (point mutation) in the 3’ untranslated region of Factor II. The 3’ untranslated region is responsible for regulation of the transcription of the gene and is not within the gene itself. The mutation is a substitution of the nucleic acid adenine (A) for a normal guanine (G) at position 20210 and is commonly referred to as G20210A. Since the mutation is in the untranslated region, the resulting protein is not structurally affected, just the rate at which it is made. Prothrombin is a precursor of thrombin, which is the principal enzyme in the blood coagulation system. It converts circulating fibrinogen into its insoluble derivative, fibrin, resulting in a clot. It is not clear precisely why increased prothrombin and thrombin lead to a state of hypercoagulability.
Individuals may carry the mutation on one chromosome (heterozygous) or on both chromosomes (homozygous). Heterozygotes have a 3 to 7-fold increased risk of developing venous thrombosis. Individuals who are homozygous for the mutation are extremely rare. For heterozygous patients using oral contraceptives, the risk of thrombosis increases.
The Factor II polymorphism should be evaluated in patients for whom testing is undertaken to identify risk factors associated with venothrombotic disease, including activated protein C resistance, and deficiencies of protein S, protein C, and antithrombin. The Factor II mutation is assessed in the laboratory using technologies that enable identification of a single base pair change. Results are reported as homozygous wild-type (no mutation detected), heterozygous (mutation detected on a single chromosome), and homozygous mutant (mutation detected on both chromosomes). Because this is a genetic test, this test only needs to be performed once in a patient’s lifetime.
- Evaluation of thrombotic risk
- Venous thromboembolism
- Deep vein thrombosis (DVT)
- Pulmonary embolism
- Coronary artery disease, and/or stroke
- Recurrent miscarriages
- Venous thrombosis in women taking oral contraceptives or hormone replacement
- Other thrombolitic problems
Positive in:
- Patients with family history of hypercoagulability secondary to factor II (prothrombin) G20210A mutation
- Patients with history of DVT
- Recurrent miscarriages
- Venous thrombosis, stroke
Heterozygous individuals with G20210A mutation have an approximately 3-fold increase risk in venous thrombosis. Homozygosity for this mutation is very rare and the increase risk for these individuals is not known.
No Mutation Detected (Negative for mutation analyzed)
Whole Blood EDTA (Lavender).
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- Blood. 2011 Aug 25;118(8):2055-61; quiz 2375. [PMID: 21659542]
- Ann Intern Med. 1998 Jul 15;129(2):89-93. [PMID: 9669991]
- Blood. 1996 Nov 15;88(10):3698-703. [PMID: 8916933]
- Mol Genet Metab. 2005;86:91. [PMID: 16185908]
- Arch Intern Med. 2006;166:729. [PMID: 16606808]
- Clin Chem. 1997 Sep;43(9):1678-83. [PMID: 9299960]
- Arterioscler Thromb Vasc Biol. 1999 Mar;19(3):700-3. [PMID: 10073976]
- Haematologica. 2007 Aug;92(8):1107-14. [PMID: 17650440]